Clinical Trial Update: Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn [Phase 2]

View source ↗

Summary

Phase 2 trial of Remodulin as add-on therapy for persistent pulmonary hypertension of the newborn has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Pulmonary Hypertension of the Newborn

Drugs mentioned

• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Persistent Pulmonary Hypertension of the Newborn | Phase 2 | Status: TERMINATED | Results posted: 2024-03-05